Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO + cyclosporine A + stanozolol vs cyclosporine A + stanozolol in newly diagnosed non-severe aplastic anemia
ChiCTR2600128749Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of arsenic trioxide in aplastic anemia (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
arsenic trioxide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2600128749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128749.